Syndax Pharmaceuticals Inc (NASDAQ: SNDX) on Monday, plunged -5.35% from the previous trading day, before settling in for the closing price of $16.06. Within the past 52 weeks, SNDX’s price has moved between $8.58 and $22.50.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -15.16%. The company achieved an average annual earnings per share of 14.16%. With a float of $83.34 million, this company’s outstanding shares have now reached $86.06 million.
Syndax Pharmaceuticals Inc (SNDX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Syndax Pharmaceuticals Inc is 3.25%, while institutional ownership is 119.44%. The most recent insider transaction that took place on Sep 08 ’25, was worth 2,582,021. In this transaction Chief Executive Officer of this company sold 157,307 shares at a rate of $16.41, taking the stock ownership to the 298,661 shares. Before that another transaction happened on Sep 08 ’25, when Company’s Director proposed sale 157,307 for $17.04, making the entire transaction worth $2,680,511.
Syndax Pharmaceuticals Inc (SNDX) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.98 earnings per share (EPS) for the period topping the consensus outlook (set at -1.06) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.61 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.16% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 70.37% during the next five years compared to -15.16% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Syndax Pharmaceuticals Inc (SNDX) is currently performing well based on its current performance indicators. A quick ratio of 4.55 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.90, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -1.75 in one year’s time.
